US Patent 10544212 Anti-IL-33 antibodies, compositions, methods and uses thereof
Patent 10544212 was granted and assigned to Pfizer Limited on January, 2020 by the United States Patent and Trademark Office.
All edits
Edits on 10 Apr, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 11 Dec, 2023
Golden AI
Edits made to:
Article (+170 characters)
Article
Patent abstract
The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to IL-33, as well as uses, and associated methods thereof.
Edits on 26 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
0
Current Assignee
0
Patent Jurisdiction
Patent Number
105442120
Date of Patent
January 28, 2020
0Patent Application Number
154951720
Date Filed
April 24, 2017
0Patent Citations Received
Patent Primary Examiner
Edits on 24 Apr, 2023
Golden AI
Infobox
Patent Citations Received
Edits on 24 Sep, 2022
Golden AI
Infobox
Patent Citations Received
Edits on 23 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
0
Current Assignee
0
Patent Jurisdiction
Patent Number
105442120
Date of Patent
January 28, 2020
0Patent Application Number
154951720
Date Filed
April 24, 2017
0Patent Citations Received
Patent Primary Examiner
Edits on 16 Feb, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent citations received
Edits on 1 Feb, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 10544212 Anti-IL-33 antibodies, compositions, methods and uses thereof
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10544212
Date of patent
January 28, 2020
Patent application number
15495172
Date Filed
April 24, 2017
Patent primary examiner
Find more entities like US Patent 10544212 Anti-IL-33 antibodies, compositions, methods and uses thereof
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
